What it's for (Indications)
- Amlodipine besylate + atorvastatin calcium trihydrate is indicated for the treatment of patients for whom therapy with both amlodipine and atorvastatin is appropriate.
- This includes individuals requiring treatment for hypertension (high blood pressure) and/or chronic stable angina pectoris, in conjunction with primary hypercholesterolemia, mixed dyslipidemia, or for the reduction of cardiovascular risk in patients with multiple risk factors.
- It is particularly suitable for patients who have demonstrated stable control on individual monotherapies of amlodipine and atorvastatin at equivalent doses, offering the advantage of a single combination pill to improve adherence and simplify treatment regimens.
- This fixed-dose combination targets the concurrent management of cardiovascular risk factors, enhancing the primary and secondary prevention strategies against major cardiovascular events such as myocardial infarction and stroke, especially in high-risk populations.
- Consideration should be given to appropriate dosing of each component based on individual patient needs and response to therapy.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of amlodipine besylate + atorvastatin calcium trihydrate must be individualized based on the patient's current amlodipine and atorvastatin doses, the severity of hypertension or angina, and the degree of dyslipidemia requiring treatment. This fixed-dose combination is available in various strengths combining different doses of amlodipine (e.g., 5 mg, 10 mg) and atorvastatin (e.g., 10 mg, 20 mg, 40 mg, 80 mg). The usual starting dose for patients requiring both therapies is typically one tablet once daily, with the specific strength chosen to provide the appropriate therapeutic effect for each component. Dosage adjustments, if necessary, should be made after at least 1-2 weeks of therapy to allow for full therapeutic response and careful monitoring of blood pressure and lipid levels. Patients should be advised to take the medication at approximately the same time each day, with or without food, as directed by their healthcare provider. It is crucial not to exceed the maximum recommended daily doses for either amlodipine or atorvastatin contained within the combination product, and to consult a healthcare professional before making any dosage changes. |
Safety & Warnings
Common Side Effects
- The most common side effects associated with amlodipine besylate + atorvastatin calcium trihydrate are generally mild to moderate and may include peripheral edema (swelling of the ankles or feet), headache, dizziness, flushing, fatigue, nausea, abdominal pain, diarrhea, and myalgia (muscle pain).
- Other reported side effects can encompass nasopharyngitis, arthralgia (joint pain), and elevations in liver transaminases, particularly with atorvastatin.
- Less common but more serious adverse reactions may include rhabdomyolysis (severe muscle breakdown), hepatitis, pancreatitis, anaphylaxis, and severe skin reactions.
- Patients should be educated on recognizing symptoms of serious adverse effects, such as unexplained muscle pain, tenderness or weakness, dark urine, yellowing of the skin or eyes, severe abdominal pain, or symptoms of an allergic reaction (e.
- g.
- , rash, hives, swelling of the face/lips/tongue/throat, difficulty breathing), and instructed to seek immediate medical attention if these occur.
- Regular monitoring for adverse effects, including lipid panels and liver function tests, is recommended during therapy.
Serious Warnings
- Black Box Warning: This specific fixed-dose combination product (amlodipine besylate + atorvastatin calcium trihydrate) does not carry an FDA-mandated Black Box Warning. However, it is imperative for healthcare providers and patients to be aware of the significant risks associated with its individual components, particularly atorvastatin, which warrants serious attention. Atorvastatin, like other HMG-CoA reductase inhibitors (statins), is associated with a risk of myopathy, which can progress to rhabdomyolysis, a potentially life-threatening condition characterized by muscle breakdown, myoglobinuria, and acute renal failure. The risk of myopathy/rhabdomyolysis is dose-related and significantly increased by certain concomitant medications that inhibit the CYP3A4 enzyme (e.g., cyclosporine, certain antifungals, macrolide antibiotics, HIV protease inhibitors) or other lipid-lowering therapies such as fibrates. Patients should be promptly advised to report any unexplained muscle pain, tenderness, or weakness. Additionally, statins can cause elevations in liver transaminases, and liver function tests should be performed prior to and periodically during treatment. Patients with active liver disease or unexplained persistent transaminase elevations should not use this medication.
- This fixed-dose combination carries several serious warnings primarily related to its individual components.
- Patients treated with atorvastatin are at risk for myopathy and rhabdomyolysis, a severe muscle condition that can lead to kidney failure.
- The risk is dose-dependent and increased by concomitant use of strong CYP3A4 inhibitors (e.
- g.
- , cyclosporine, macrolide antibiotics, azole antifungals, certain protease inhibitors), gemfibrozil, niacin, or in patients with hypothyroidism or renal impairment.
- Liver enzyme abnormalities, including persistent elevations in serum transaminases, have been reported with statin use, necessitating liver function tests prior to and periodically during treatment.
- Amlodipine can cause symptomatic hypotension, especially with initial dosing or dose increases, and may rarely exacerbate angina or precipitate acute myocardial infarction upon initiation or dose titration, particularly in patients with severe obstructive coronary artery disease.
- Caution is advised in patients with severe aortic stenosis or severe heart failure.
- Patients should be instructed to report any unexplained muscle pain, tenderness, or weakness, or signs of liver injury (e.
- g.
- , fatigue, anorexia, right upper quadrant discomfort, dark urine, jaundice) immediately.
- Due to the potential for interactions, a comprehensive review of all concomitant medications is essential before initiating therapy and throughout treatment.
How it Works (Mechanism of Action)
Amlodipine besylate is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and myocardial cells. This leads to peripheral arterial vasodilation, resulting in a reduction in peripheral vascular resistance and lowering of blood pressure (antihypertensive effect). It also causes coronary vasodilation, which increases myocardial oxygen supply, thereby reducing the frequency and severity of angina attacks (antianginal effect). Amlodipine's actions are specific to voltage-dependent calcium channels and it does not significantly affect sinoatrial or atrioventricular nodal conduction at therapeutic concentrations. Atorvastatin calcium trihydrate is an HMG-CoA reductase inhibitor (statin). It selectively and competitively inhibits HMG-CoA reductase, the rate-limiting enzyme that catalyzes the conversion of 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor of sterols, including cholesterol. This inhibition leads to a decrease in hepatic cholesterol synthesis, which in turn upregulates the expression of LDL receptors on hepatocyte surfaces. The increased number of LDL receptors enhances the uptake and catabolism of circulating LDL-cholesterol. Atorvastatin also reduces VLDL and triglyceride levels, and increases HDL-cholesterol to a lesser extent, thereby modifying the overall lipid profile to reduce cardiovascular risk.
Commercial Brands (Alternatives)
No other brands found for this formula.